tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

PCRX Stock Latest News

Pacira Ends Hip Osteoarthritis Injection Study for ZILRETTA: What Investors Should Know
Company AnnouncementsPacira Ends Hip Osteoarthritis Injection Study for ZILRETTA: What Investors Should Know
1d ago
PCRX
Pacira joins PROBE Consortium
PremiumThe Fly
Pacira joins PROBE Consortium
5d ago
PCRX
Pacira initiated with an Equal Weight at Barclays
PremiumThe Fly
Pacira initiated with an Equal Weight at Barclays
15d ago
PCRX
Pacira reports inducement grants under Nasdaq listing rule
PremiumThe Fly
Pacira reports inducement grants under Nasdaq listing rule
20d ago
PCRX
Pacira announces results from 12-month pilot study on iovera
PremiumThe Fly
Pacira announces results from 12-month pilot study on iovera
21d ago
PCRX
Pacira files patent infringement lawsuits against WhiteOak Group and Qilu
PremiumThe FlyPacira files patent infringement lawsuits against WhiteOak Group and Qilu
27d ago
PCRX
Pacira Pharmaceuticals Faces Revenue Decline Amid Generic Competition and Patent Challenges, Analyst Issues Sell Rating
Premium
Ratings
Pacira Pharmaceuticals Faces Revenue Decline Amid Generic Competition and Patent Challenges, Analyst Issues Sell Rating
1M ago
PCRX
Pacira Pharmaceuticals: Positioned for Growth with NOPAIN Act and Innovative Therapies
Premium
Ratings
Pacira Pharmaceuticals: Positioned for Growth with NOPAIN Act and Innovative Therapies
1M ago
PCRX
Pacira assumed with a Buy at H.C. Wainwright
PremiumThe Fly
Pacira assumed with a Buy at H.C. Wainwright
1M ago
PCRX
Pacira BioSciences Reports Strong Q3 Growth Amid Challenges
PremiumCompany Announcements
Pacira BioSciences Reports Strong Q3 Growth Amid Challenges
2M ago
PCRX
Pacira BioSciences Reports Strong Q3 2025 Results
PremiumCompany Announcements
Pacira BioSciences Reports Strong Q3 2025 Results
2M ago
PCRX
Pacira reports Q3 EPS 70c, consensus 65c
PremiumThe Fly
Pacira reports Q3 EPS 70c, consensus 65c
2M ago
PCRX
Pacira cuts FY25 revenue view to $725M-$735M from $730M-$750M
PremiumThe FlyPacira cuts FY25 revenue view to $725M-$735M from $730M-$750M
2M ago
PCRX
Pacira concludes patient enrollment in Part A of Phase 2 study of PCRX-201
Premium
The Fly
Pacira concludes patient enrollment in Part A of Phase 2 study of PCRX-201
2M ago
PCRX
Pacira enters exclusive license, collaboration agreement with AmacaThera
Premium
The Fly
Pacira enters exclusive license, collaboration agreement with AmacaThera
2M ago
PCRX
Pacira presents updated three-year results of PCRX-201
PremiumThe Fly
Pacira presents updated three-year results of PCRX-201
2M ago
PCRX
Pacira (PCRX) Q3 Earnings Cheat Sheet
PremiumPre-Earnings
Pacira (PCRX) Q3 Earnings Cheat Sheet
2M ago
PCRX
Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
PremiumCompany Announcements
Pacira’s Pediatric Analgesia Study: A Potential Game-Changer for Postoperative Pain Management
2M ago
PCRX
Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know
PremiumCompany Announcements
Pacira’s Innovative Study on Knee OA Pain Management: What Investors Need to Know
2M ago
PCRX
Pacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment
PremiumCompany AnnouncementsPacira’s Phase 2 Study: A New Approach to Hip Osteoarthritis Treatment
2M ago
PCRX
Pacira’s New Osteoarthritis Treatment: A Promising Clinical Study Update
Premium
Company Announcements
Pacira’s New Osteoarthritis Treatment: A Promising Clinical Study Update
2M ago
PCRX
Pacira’s ZILRETTA Study: A Potential Game-Changer for Osteoarthritis Pain Management
Premium
Company Announcements
Pacira’s ZILRETTA Study: A Potential Game-Changer for Osteoarthritis Pain Management
2M ago
PCRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >